Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 287 results for corticosteroids

  1. Infantile haemangioma: topical timolol (ESUOM47)

    Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

    Evidence summary
    Published
    14 August 2015

  2. What is the clinical and cost effectiveness of prednisolone, budesonide, and beclometasone in addition to aminosalicylates compared with each other and with aminosalicylate monotherapy for the induction of remission for people with mild-to-moderate ulcerative colitis?

    To find out why the committee made the research recommendation on corticosteroids for the induction of remission in mild-to-moderate...

    Research recommendation
    Published
    25 October 2019

  3. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (HTG399)

    Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.

    HealthTech guidance
    Published
    27 January 2016
    View recommendations

    Sections for HTG399

  4. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

    Technology appraisal guidance
    Last updated
    10 August 2017
    View recommendations

    Sections for TA190

  5. Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

    Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    23 September 2009
    View recommendations

    Sections for TA181

  6. Inducing labour (NG207)

    This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.

    NICE guideline
    Published
    4 November 2021
    View recommendations

    Sections for NG207

  7. Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

    Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.

    Technology appraisal guidance
    Published
    26 June 2019
    View recommendations

    Sections for TA586

  8. Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with continued relapses?

    patients and the NHS. The primary treatment of acute relapses is with corticosteroids, using a variety of different dosing regimens with...

    Research recommendation
    Published
    9 June 2015

  9. Monitoring adherence to treatment:- What is the clinical and cost effectiveness of using electronic alert systems designed to monitor and improve adherence with regular inhaled maintenance therapy in people with asthma?

    Why this is important:- Adherence with regular maintenance inhaled corticosteroids, on their own or in combination with long-acting beta...

    Research recommendation
    Published
    18 October 2018

  10. Preterm prelabour rupture of membranes: What are the relative risks and benefits of induced labour versus expectant management in women whose membranes have ruptured spontaneously between 34 and 37 weeks?

    induction. The value of antibiotic therapy and the administration of corticosteroids to the woman is unclear in this situation. A...

    Research recommendation
    Published
    15 December 2021

  11. What risk factors in people who are critically ill and have, or have had, COVID-19 as part of their acute illness are associated with developing COVID-19-associated pulmonary aspergillosis (CAPA)?

    treatments (for example, respiratory support for COVID-19, high-dose corticosteroids,interleukin-6 inhibition)• association of CAPA with...

    Research recommendation
    Published
    17 December 2021

  12. Starting asthma treatment:- In adults, young people and children with asthma who have not been treated previously, is it more clinically and cost effective to start treatment with a reliever alone (a short-acting beta2 agonist [SABA]) or with a reliever (a SABA) and maintenance therapy (such as ICS)? Are there specificprognostic features that indicate that one of these treatment options may be more appropriate for some groups?

    persistent asthma symptoms, to starting people on a low dose inhaled corticosteroid (ICS) as maintenance therapy alongside the SABA at...

    Research recommendation
    Published
    18 October 2018

  13. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

    Evidence summary
    Published
    5 January 2021

  14. FLEXISEQ for osteoarthritis (MIB80)

    NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis

    Medtech innovation briefing
    Published
    14 September 2016

  15. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

    Technology appraisal guidance
    Published
    17 November 2021
    View recommendations

    Sections for TA747